Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?

Area of Science:

• Nephrology
• Immunology
• Pathophysiology

Background:

• Idiopathic membranous nephropathy (iMN) is a leading cause of nephrotic syndrome in adults.
• Circulating autoantibodies against the M-type phospholipase A₂ receptor (anti-PLA₂R) are now recognized as a primary target in iMN.
• Diagnosis and management of iMN have historically relied on kidney biopsy.

Purpose of the Study:

• To review the diagnostic and therapeutic implications of anti-PLA₂R autoantibody testing in iMN.
• To evaluate the current evidence supporting the use of anti-PLA₂R assays in clinical practice.
• To provide recommendations on the judicious application of anti-PLA₂R testing.

Main Methods:

• Literature review of studies investigating anti-PLA₂R antibodies in iMN.
• Analysis of the clinical utility of commercially available anti-PLA₂R assays.
• Evaluation of evidence regarding the impact of anti-PLA₂R testing on diagnostic strategies and treatment guidance.

Main Results:

• The identification of anti-PLA₂R autoantibodies represents a significant advancement in understanding iMN.
• A commercially available assay for anti-PLA₂R is available, offering a potential non-invasive diagnostic tool.
• Emerging evidence suggests anti-PLA₂R testing may alter diagnostic pathways for nephrotic syndrome and guide iMN treatment.

Conclusions:

• Anti-PLA₂R autoantibodies are crucial biomarkers in iMN, potentially transforming clinical practice.
• While promising, the widespread use of anti-PLA₂R assays in routine clinical settings requires careful consideration and further validation.
• Clinicians should exercise caution and critically assess the evidence before implementing anti-PLA₂R testing for diagnostic or therapeutic decisions in iMN.